Novartis expands clinical pipeline with multi-billion dollar acquisitions
Novartis has expanded its clinical pipeline through the back to back acquisitions of Pikavation Therapeutics and Excellergy. The Swiss pharmaceutical giant is seeking to offset looming patent expiries for major brands such as Entresto and Promacta. The first transaction involves the acquisition of Pikavation Therapeutics, a subsidiary of Synnovation Therapeutics, for $3bn. Under the definitive agreement, Novartis will pay $2bn…